Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Excedrin Extra Strength OTC migraine use efficacy, safety shown, FDA cmte. agrees.

This article was originally published in The Tan Sheet

Executive Summary

EXCEDRIN EXTRA STRENGTH OTC MIGRAINE USE EFFICACY, SAFETY SHOWN by Bristol-Myers Squibb data, members of three FDA advisory committees agreed at a July 15 joint meeting in Bethesda, Md. The agency's Nonprescription Drugs and Arthritis Advisory Committees and members of the Peripheral & Central Nervous System Drugs Advisory Committee voted unanimously that the company provided adequate evidence to support the effectiveness of Excedrin Extra Strength for OTC use in migraine.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087313

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel